Supplementary Table 2. Comparison of baseline characteristics between matched cohorts: TACE vs. TKI

Characteristic	Treatment		P-value
	TACE (n=45)	TKI (n=45)	
Age (years)	57.2±12.5	57.3±11.6	0.951
Male	38 (84.4)	38 (84.4)	1.000
Etiology			1.000
Viral	34 (75.6)	34 (75.6)	
NBNC	11 (24.4)	11 (24.4)	
ECOG performance status			0.756
0	38 (84.4)	40 (88.9)	
≥1	7 (15.6)	5 (11.1)	
ALBI grade			1.000
1	33 (73.3)	33 (73.3)	
≥2	12 (26.7)	12 (26.7)	
Size (cm)			1.000
<5	6 (13.3)	6 (13.3)	
≥5	39 (86.7)	39 (86.7)	
Number			1.000
<3	19 (42.2)	18 (40.0)	
≥3	26 (57.8)	27 (60.0)	
Log (AFP)	6.8±3.7	6.5±3.8	0.710
Log (PIVKA-II)	8.2±2.3	8.1±2.7	0.935
PV invasion			0.942
None	22 (48.9)	22 (48.9)	
Segmental/lobar	17 (37.8)	18 (40.0)	
Main/contralateral	6 (13.3)	5 (11.1)	
Extrahepatic metastasis type			0.682
Nodal metastasis	17 (37.8)	14 (31.1)	
Distant metastasis	20 (44.4)	20 (44.4)	
Nodal plus distant metastasis	8 (17.8)	11 (24.4)	

Values are presented as mean±standard deviation or number (%).
TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; NBNC, non-B and non-C; ECOG, Eastern Cooperative Oncology Group; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II; PV, portal vein.